Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progression

Key Points

• Patients receiving second-line treatments showed improved progression-free survival outcomes, indicating effectiveness.
• Progression-free survival of 7.5 months was observed in patients on second-line therapies—an important metric.
• Assessment of patient outcomes following osimertinib discontinuation indicates significant gaps in treatment efficacy.
• Highlights the need for further investigations on long-term effects in advanced non-small cell lung cancer cases.